Get the Stockscreener App
38.09
0.24%
0.09
Definium Therapeutics Inc stock is traded at $38.09, with a volume of 1.13M.
It is up +0.24% in the last 24 hours and down -10.00% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
See More
Previous Close:
$38.00
Open:
$37.94
24h Volume:
1.13M
Relative Volume:
0.38
Market Cap:
$5.12B
Revenue:
-
Net Income/Loss:
$-237.54M
P/E Ratio:
-15.22
EPS:
-2.5033
Net Cash Flow:
$-145.05M
1W Performance:
-7.05%
1M Performance:
-10.00%
6M Performance:
+114.47%
1Y Performance:
+0.00%
1-Day Range:
$37.38
$38.54
1-Week Range:
$37.32
$41.34
52-Week Range:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
38.09 | 6.10B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-10-26 | Initiated | Piper Sandler | Overweight |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
DRIEHAUS CAPITAL MANAGEMENT LLC Expands Definium Therapeutics In - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX) - MarketBeat
Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results - Sahm
Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120 - TipRanks
Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America - MarketBeat
Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT - Sahm
DFTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
Definium Therapeutics Announces New Employee Inducement GrantsAugust 17, 2026 - BioSpace
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential - Investing.com Nigeria
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics (DFTX) Reports Positive Phase 3 GAD Trial Results Amid High Valuation - GuruFocus
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus
Definium Therapeutics Price Target Raised to $55.00/Share From $50.00 by Maxim Group - Moomoo
Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake - Stock Titan
Definium Therapeutics' Voyage Trial Success Reshapes Valuation Debate for Anxiety Drug - finance.biggo.com
DFTX News Today | Why did Definium Therapeutics stock go down today? - MarketBeat
Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36% - Stock Titan
Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus - Yahoo Finance
Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says - Moomoo
Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)? - Yahoo Finance
DFTX Maintained by Jones Trading -- Price Target Raised to $90.0 - GuruFocus
Definium says LSD-based pill reduces anxiety in late-stage study - Reuters
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00 at JonesTrading - MarketBeat
DFTX Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT - Yahoo Finance
DFTX Maintained by RBC Capital -- Price Target Raised to $66.00 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock - MarketBeat
DFTX Maintained by Wells Fargo -- Price Target Raised to $72 - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company - MarketBeat
JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $90 - Moomoo
Definium Phase III success with DT120 in anxiety - The Pharma Letter
Robert W. Baird Increases Definium Therapeutics (NASDAQ:DFTX) Price Target to $75.00 - MarketBeat
Canaccord raises Definium Therapeutics price target on trial data By Investing.com - Investing.com Nigeria
Canaccord raises Definium Therapeutics price target on trial data - Investing.com
DFTX Maintained by Baird -- Price Target Raised to $75.00 - GuruFocus
RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating - marketscreener.com
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study - MarketBeat
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst - Seeking Alpha
DFTX Maintained by Needham -- Price Target Raised to $66.00 - GuruFocus
Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00 - MarketBeat
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’ - TradingView
Definium Therapeutics Inc Stock (DFTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Definium Therapeutics Inc Stock (DFTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Jun 25 '26 |
Sale |
45.03 |
13,008 |
585,750 |
320,571 |
| Roberts Brandi | Chief Financial Officer |
Jun 25 '26 |
Sale |
45.03 |
3,013 |
135,675 |
209,487 |
| Barrow Robert | Chief Executive Officer |
Jun 25 '26 |
Sale |
45.03 |
29,208 |
1,315,236 |
1,098,246 |
| Karlin Daniel | Chief Medical Officer |
Jun 25 '26 |
Sale |
45.03 |
10,035 |
451,876 |
503,282 |
| Wiley Matthew T. | Chief Commercial Officer |
Jun 25 '26 |
Sale |
45.03 |
2,867 |
129,101 |
174,633 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):